Quarterly report pursuant to Section 13 or 15(d)

Revenue - Additional Information (Detail)

v3.21.2
Revenue - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Feb. 28, 2021
Disaggregation Of Revenue [Line Items]          
Revenue $ 516,000 $ 0 $ 12,566,000 $ 0  
Income tax expense (50,000) 0 (3,088,000) (3,144,000)  
Exclusive License And Collaboration Agreement          
Disaggregation Of Revenue [Line Items]          
Non refundable upfront payment received     10,000,000.0    
Transaction price     12,100,000    
Fixed upfront cash payment     10,000,000.0    
Amount related to withholding tax obligations     1,100,000    
Revenue recognized     1,100,000    
Income tax expense     1,100,000    
Exclusive License And Collaboration Agreement | Maximum          
Disaggregation Of Revenue [Line Items]          
Potential development and commercial milestones yet to receive         $ 110,000,000.0
Asset Purchase Agreement | Cypralis Limited          
Disaggregation Of Revenue [Line Items]          
Revenue recognized 0   0    
License Agreement | Waterstone Pharmaceutical HK Limited          
Disaggregation Of Revenue [Line Items]          
Revenue recognized $ 0   0    
Sales Revenue Net | Customer Concentration Risk | Wholesaler One          
Disaggregation Of Revenue [Line Items]          
Percentage of gross revenue 55.00%        
Sales Revenue Net | Customer Concentration Risk | Wholesaler Two          
Disaggregation Of Revenue [Line Items]          
Percentage of gross revenue 20.00%        
Sales Revenue Net | Customer Concentration Risk | Wholesaler Three          
Disaggregation Of Revenue [Line Items]          
Percentage of gross revenue 16.00%        
Product Revenue, Net          
Disaggregation Of Revenue [Line Items]          
Revenue $ 516,000 $ 0 $ 516,000 $ 0